2m 2m 2m 2m 2m 2m 2m
AMNEAL PHRMCTL-A (AMRX)
NASDAQ
$16.74+$0.07 (+0.45%)
Price as of Jun 23, 2026 7:49 PM EDT- $5.1BMarket Cap
- 104.92%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
AMNEAL PHRMCTL-A (AMRX)
$16.74+$0.07 (+0.45%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 3.0B +8.05% | 2.8B +16.73% | 2.4B +8.20% | 2.2B +5.67% | |
Cost of Revenue | 1.9B +7.44% | 1.8B +12.74% | 1.6B +11.05% | 1.4B +8.79% | |
Gross Profit | 1.1B +9.10% | 1.0B +24.36% | 820.6M +4.57% | 784.7M +2.05% | |
Sales and Marketing Expense | 526.8M +10.58% | 476.4M +10.88% | 429.7M +7.50% | 399.7M +9.36% | |
Research and Development Expense | -186.2M -2.38% | -190.7M +16.32% | -163.9M -16.22% | -195.7M -3.05% | |
Depreciation and Amortization Expense | 166.3M -4.21% | 173.6M +6.37% | 163.2M -5.15% | 172.1M -0.37% | |
Total Operating Expenses | 1.9B +7.44% | 1.8B +12.74% | 1.6B +11.05% | 1.4B +8.79% | |
Operating Profit | 394.1M +58.06% | 249.3M +21.99% | 204.4M +315.29% | -94.9M -162.16% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -241.1M -6.77% | -258.6M +22.77% | -210.6M +32.99% | -158.4M +16.18% | |
Interest Income and Expense and Net | -241.1M -6.77% | -258.6M +22.77% | -210.6M +32.99% | -158.4M +16.18% | |
Total Nonoperating Income and Expense | -254.9M -16.25% | -304.3M +24.40% | -244.6M +59.69% | -153.2M +26.25% | |
Income before Taxes | 139.2M +353.05% | -55.0M +36.61% | -40.3M -83.77% | -248.1M -891.07% | |
Income Taxes | 11.3M -40.22% | 18.9M +123.18% | 8.5M +26.87% | 6.7M -40.50% | |
Extraordinary Items | 0 N/A | 0 -100.00% | 30.8M +137.47% | 13.0M +1,726.76% | |
Net Income | 72.1M +197.54% | -73.9M +51.63% | -48.7M -80.88% | -254.8M -1,363.21% | |
Net Income from Continuing Operations Applicable to Common | 139.2M +219.10% | -116.9M +39.16% | -84.0M -35.38% | -130.0M -1,323.51% | |
Basic EPS and Net Income | 0.23 +160.53% | -0.38 -20.83% | -0.48 -44.19% | -0.86 -1,328.57% | |
Diluted EPS and Net Income | 0.22 +157.89% | -0.38 -20.83% | -0.48 -44.19% | -0.86 -1,328.57% | |
Basic Weighted Average Shares | 313.4M +1.42% | 309.0M +75.42% | 176.1M +16.69% | 150.9M +1.36% | |
Diluted Weighted Average Shares | 324.8M +5.12% | 309.0M +75.42% | 176.1M +16.69% | 150.9M -0.58% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 282.0M +155.11% | 110.6M +20.77% | 91.5M +252.41% | 26.0M -89.52% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 282.0M +155.11% | 110.6M +20.77% | 91.5M +252.41% | 26.0M -89.52% | |
Total Current Assets | 1.9B +20.37% | 1.6B +15.24% | 1.4B -2.41% | 1.4B -7.12% | |
Accumulated Depreciation | 606.2M +7.57% | 563.5M +10.92% | 508.0M +13.91% | 446.0M +13.03% | |
Property and Plant and Equipment and Net | 442.9M +4.25% | 424.9M -5.06% | 447.6M -4.73% | 469.8M -8.62% | |
Total Long-Term Assets | 57.8M -3.87% | 60.1M +8.31% | 55.5M -46.21% | 103.2M +400.71% | |
Total Assets | 3.7B +5.05% | 3.5B +0.83% | 3.5B -8.60% | 3.8B -3.56% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | 359,000 -85.77% | |
Total Short-Term Debt | 6.8M -97.91% | 324.2M +52.12% | 213.1M +130.55% | 92.4M +17.80% | |
Total Current Liabilities | 881.6M -21.96% | 1.1B +33.45% | 846.6M +12.46% | 752.8M +11.16% | |
Total Long-Term Debt | 2.6B +18.66% | 2.2B -9.40% | 2.4B -9.34% | 2.6B -3.18% | |
Total Long-Term Liabilities | 2.8B +15.50% | 2.4B -5.79% | 2.6B -9.62% | 2.8B -1.42% | |
Total Liabilities | 914.9M -21.40% | 1.2B +31.75% | 883.5M +10.32% | 800.8M +9.87% | |
Retained Earnings | -535.0M -11.87% | -607.1M +23.85% | -490.2M +20.68% | -406.2M +47.06% | |
Total Stockholders Equity | -70.8M -35.21% | -109.3M -652.38% | 19.8M -93.37% | 298.4M -17.18% | |
Total Shares Outstanding | 314.6M +1.51% | 309.9M +1.08% | 306.6M +0.97% | 303.6M +0.69% | |
Cash Flow | |||||
Cash from Operating Activities | 340.0M +15.21% | 295.1M -14.61% | 345.6M +430.84% | 65.1M -73.08% | |
Capital Expenditures | 70.1M +34.93% | 51.9M +20.15% | 43.2M -6.88% | 46.4M -2.77% | |
Cash from Investing Activities | -112.3M +78.21% | -63.0M -8.95% | -69.2M -60.31% | -174.3M -10.23% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -31.5M -85.11% | -211.8M -0.37% | -212.6M +99.37% | -106.6M -22.81% | |
Financials Ratio | |||||
Gross Margin | 36.88% +0.98% | 36.52% +6.54% | 34.28% -4.70% | 35.97% -4.87% | |
Operating Margin | 13.05% +46.29% | 8.92% +4.51% | 8.54% +298.99% | -4.29% -158.83% | |
Return on Assets | 2.01% +194.74% | -2.12% +58.10% | -1.34% -79.65% | -6.58% -1,396.93% | |
Return on Equity | -80.04% -148.47% | 165.11% +639.17% | -30.62% -60.41% | -77.35% -1,372.50% | |
Revenue Growth | 8.05% -51.89% | 16.73% +104.09% | 8.20% +44.63% | 5.67% +11.62% | |
Current Ratio | 2.17 +54.25% | 1.41 -13.65% | 1.63 -13.22% | 1.88 -16.45% | |
Cash Ratio | 0.32 +226.76% | 0.10 -9.44% | 0.11 +213.33% | 0.03 -90.57% | |
Debt-to-Equity Ratio | -36.33 +59.68% | -22.75 -117.32% | 131.40 +1,339.40% | 9.13 +17.62% | |
Debt-to-Assets Ratio | 0.70 -1.52% | 0.71 -5.14% | 0.75 +4.39% | 0.72 +1.01% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow